Navigation Links
Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting

llaboration with Novartis covering Genelabs' non-nucleoside HCV polymerase inhibitors.

"The data presented today clearly support the further investigation of non-nucleoside polymerase inhibitors for the future treatment of HCV infection," said Ronald C. Griffith, Ph.D., Genelabs' Chief Scientific Officer. "Furthermore, we believe future treatment of HCV is likely to involve combinations of antiviral drugs and these data suggest that combinations of this type of non-nucleoside agent with interferon or other likely therapeutic drugs, such as nucleoside chain terminators or protease inhibitors, may be feasible."

About Genelabs Technologies

Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also developing a late-stage product for lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate. For more information, please visit www.genelabs.com.

NOTE: Genelabs(R) and the Genelabs logo are registered trademarks and Prestara(TM) is a trademark of Genelabs Technologies, Inc.

NOTE ON FORWARD LOOKING STATEMENTS AND RISKS: This press release contains forward-looking statements including statements on the feasibility of non-nucleoside polymerase inhibitors for the future treatment of HCV infection and the prospects fo
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
4. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
5. Micell Technologies Presents Data on Novel Drug-Eluting Stents
6. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
7. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:8/27/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... therapies, today announced that it will release its year-end ... 2015 on Friday, September 4, 2015. ... call and live webcast for investors, analysts and other ...
(Date:8/27/2015)... , Spain and CAMBRIDGE, Mass. , Aug. ... be presenting at the Rodman & Renshaw 17th Annual Global ... Held at the St. Regis Hotel, ORYZON will be represented ... Dr. Buesa will present ... EDT, at the Fontainebleau Room (2nd Floor).  The company is ...
(Date:8/27/2015)... 2015 The global compression ... 3.96 billion by 2022, according to a new report ... venous disorders such as deep vein thrombosis, leg ulcers, ... the key driver.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757) , ... also expected to boost market growth over the forecast ...
Breaking Medicine Technology:DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 2DelMar Pharmaceuticals to Announce Fiscal 2015 Year-End Financial Results on September 4, 2015 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 2Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 5
... Mass., Jan. 23, 2012  Boston Scientific Corporation (NYSE: ... District of New Jersey has found all the asserted patents ... invalid and entered judgment in favor of Boston Scientific. ... Johnson alleged that Boston Scientific,s PROMUS® Everolimus-Eluting Coronary Stent System ...
... Premier Research Group announces the appointment of Etienne Drouet ... this position, Mr. Drouet will play a leading role ... Premier Research,s growing portfolio of oncology business. ... oncology acumen serving the needs of our customers," said ...
Cached Medicine Technology:Boston Scientific Announces Favorable Ruling in Patent Infringement Case 2Boston Scientific Announces Favorable Ruling in Patent Infringement Case 3Premier Research Names Etienne Drouet Executive Director, Oncology Europe 2
(Date:8/27/2015)... ... , ... Healthpointe is proud to welcome Dr. Ted Priebe, O.M.D., CEO of ... practice Chinese Needle Therapy since 1983, Dr. Priebe specializes in the study and treatment ... in Healthpointe’s La Mirada clinic and Garden Grove clinic. , Acupuncture ...
(Date:8/27/2015)... ... ... In addition to its existing Doctor of Philosophy in Leadership and Doctor of ... campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor of Nursing Practice ... the highest level of clinical nursing practice. , “Our vision is to graduate ...
(Date:8/27/2015)... ... August 27, 2015 , ... For the first ... machine with the Nutri Ninja® Auto-iQ Pro Complete and Nutri Ninja Auto-iQ Compact ... that takes drink customization to a whole new level. This line of Nutri ...
(Date:8/27/2015)... ... ... Susan Harris and the team at LifeStream Health Centre & ... post-menopause, chemotherapy, and child birth. , The MonaLisa Touch is a unique ... tissue, revitalizing cells so they make more collagen, an essential component in vaginal cell ...
(Date:8/27/2015)... ... 27, 2015 , ... Since its launch on August 16, ... offices in three counties, LA, Orange and San Bernardino. Their twenty physicians ... by Dr. Richy Agajanian, the Oncology Institute of Hope and Innovation is dedicated ...
Breaking Medicine News(10 mins):Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 4Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2
... of a naturally occurring fat molecule have the potential ... or damage, researchers report. , Through both the ... smooth, young skin inevitably becomes coarse and wrinkled. The ... both lower the production of new collagen while increasing ...
... percent of patients who recently underwent liver transplantation ... factors included having had biliary-enteric anastomosis (choledocho-jejunal or ... more than four red blood cell units transfused. ... of Liver Transplantation, a journal by John Wiley ...
... internet pharmacies and life-saving medicines, purchased online was ... Global Forum ... June 5 The European Alliance for Access ... research report,-- The Counterfeiting Superhighway. The report revealed ...
... Reps. Pomeroy, Capito, Berkley Leading,Respective Chambers, Letter Effort ... to Seniors, Medicare-Financed Nursing Home Care, WASHINGTON, ... and Alliance for Quality Nursing Home Care today ... and Reps. Earl,Pomeroy (D-ND), Shelley Moore Capito (R-WV) ...
... June 5 Fort Dodge Animal Health, a,division of ... of,ProHeart(R) 6, a unique heartworm preventative, to the U.S. ... Food and Drug,Administration,s Center for Veterinary Medicine (CVM) of ... support the decision,to return this life-saving product to the ...
... to restore function to a paralyzed limb? Or to ... are two of the several topics that will be ... by Case Western Reserve University. The conference will be ... Conference Center in Cleveland. , "Neural interfaces have already ...
Cached Medicine News:Health News:Researchers determine risk factors for infection after liver transplantation 2Health News:Death on the Net? Over 60% of Medicines Sold by Online Pharmacies are Fake 2Health News:Death on the Net? Over 60% of Medicines Sold by Online Pharmacies are Fake 3Health News:AHCA, Alliance Praise New Bipartisan, Bi-Cameral Effort Urging Bush Administration to Forego Medicare Cuts 2Health News:AHCA, Alliance Praise New Bipartisan, Bi-Cameral Effort Urging Bush Administration to Forego Medicare Cuts 3Health News:Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market 2Health News:Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market 3Health News:Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market 4Health News:Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market 5Health News:Premier conference on neurotechnology and deep brain stimulation to be held in Cleveland June 16-18 2
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... Consensus knee system continues the "Consensus Concept" ... with the diversified experience of a Scientific ... knee system that incorporates state-of-the-art features. Consensus ... joint and implant stability and allow near ...
Profix total knee system is intended for cemented use only....
Medicine Products: